Antengene Announces Publication of Abstract on XPO1 Inhibitor Selinexor in Relapsed or Refractory Multiple Myeloma at ASCO 2021 and EHA 2021

Jun 04, 2021View PDF

-Results from the MARCH trial showed an ORR of 33.3% in triple-class-exposed RRMM patients with the Sd regimen, and 44.4% in patients who previously received CAR-T therapies-

-Selinexor is currently the only commercially available XPO1 inhibitor-

 

Shanghai and Hong Kong, PRC, June 4 2021–Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, announced that the results from the Phase II MARCH trial of selinexor plus low dose dexamethasone (the Sd regimen) for the treatment of Chinese patients with relapsed or refractory multiple myeloma (RRMM) are published at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting and the 2021 European Hematology Association (EHA) Virtual Congress.

 

Data from a planned analysis of the first 60 treated patients with a median follow-up of 9.5 months demonstrates an overall response rate (ORR) of 26.7%. Meanwhile, an ORR of 33.3% was achieved with the Sd regimen in triple-class-exposed (IMiDs, PIs and anti-CD38 mAb) patients, and an ORR of 44.4% was achieved in patients that previously received CAR-T therapies. In Chinese patients that were refractory to both immunomodulatory agents (IMiDs) and proteasome inhibitors (PIs), results from the MARCH trial have confirmed the efficacy and manageable safety profile of the Sd regimen, which is consistent with that observed in the STORM trial, the data from which supported the accelerated approval of selinexor by the U.S. Food and Drug Administration (FDA).

 

Selinexor, the first-in-class XPO1 inhibitor approved for the treatment of RRMM and relapsed or refractory diffuse large B-cell lymphoma (RRDLBCL), has five regimens added to the National Comprehensive Cancer Network (NCCN®) Guidelines and four regimens added to the Chinese Society of Clinical Oncology (CSCO) Diagnosis and Treatment Guidelines. Antengene has submitted new drug applications (NDAs) for selinexor in five APAC markets and anticipates receiving approvals for these NDAs in Q4 2021 and Q1 2022.

 

ASCO 2021 Annual Meeting

The full abstract is now available at:

https://meetinglibrary.asco.org/record/195519/abstract

Abstract Title:

Results of the phase 2 MARCH Study: Oral ATG-010 (Selinexor) plus low dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma (RRMM) previously treated with an immunomodulatory agent (IMiD) and a proteasome inhibitor (PI).

Abstract #: e20002

 

EHA2021 Virtual Congress

The full abstract is now available at:

https://library.ehaweb.org/eha/2021/eha2021-virtual-congress/324343/weijun.fu.phase.2.march.study.of.oral.atg-010.plus.low.dose.dexamethasone.in.html

Abstract Title:

Results of the phase 2 MARCH Study: Oral ATG-010 (Selinexor) plus low dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma (RRMM) previously treated with an immunomodulatory agent (IMiD) and a proteasome inhibitor (PI).

Abstract #: PB1670

 

About Antengene

Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK) is a leading clinical-stage R&D driven biopharmaceutical company focused on innovative medicines for oncology and other life-threatening diseases. Antengene aims to provide the most advanced anti-cancer drugs to patients in the Asia Pacific Region and around the world. Since its establishment in 2017, Antengene has built a broad and expanding pipeline of clinical and pre-clinical stage assets through partnerships as well as in-house drug discovery, and obtained 15 investigational new drug (IND) approvals and submitted 5 new drug applications (NDA) in multiple markets in Asia Pacific. Antengene’s vision is to “Treat Patients Beyond Borders”. Antengene is focused on and committed to addressing significant unmet medical needs by discovering, developing and commercializing first-in-class/best-in-class therapeutics.

 

Forward-looking statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.

 

*The STORM trial, initiated by Karyopharm, is a multicenter, single-arm, open-label Phase IIb trial designed to evaluate the efficacy of selinexor plus dexamethasone (Xd) in patients with relapsed or refractory multiple myeloma.